XM does not provide services to residents of the United States of America.
A
A

AstraZeneca

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

UK Stocks-Factors to watch on June 18

UPDATE 1-UK Stocks-Factors to watch on June 18 Updates opening levels, adds news items June 18 - Britain's FTSE 100 .FTSE index opened up 0.52% on Tuesday. * ASHTEAD GROUP: British equipment rental firm Ashtead Group AHT.L forecast on Tuesday a slower growth in group rental revenue for fiscal 2025 after a 10% jump in 2024. * ASTRAZENECA: AstraZeneca AZN.L said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stag
A
A
U

AstraZeneca's breast cancer drug combination fails in late-stage trial

UPDATE 1-AstraZeneca's breast cancer drug combination fails in late-stage trial Adds details and comment in paragraphs 3-5 June 18 (Reuters) - AstraZeneca AZN.L said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patients with a type of breast cancer.
A

AstraZeneca's breast cancer drug combination fails in late-stage trial

AstraZeneca's breast cancer drug combination fails in late-stage trial June 18 (Reuters) - AstraZeneca AZN.L said on Tuesday its breast cancer drug, Truqap, in combination with chemotherapy agent, paclitaxel, did not meet its main goals in a late-stage trial to improve overall survival of patients with a type of breast cancer. Triple-negative breast cancer remains one of the most challenging forms of disease to treat due to the lack of known actionable biomarker targets, and chemotherapy-based r
A

Astrazeneca Says Capitello-290 Phase III Trial For Truqap Did Not Meet Dual Primary Endpoints

BRIEF-Astrazeneca Says Capitello-290 Phase III Trial For Truqap Did Not Meet Dual Primary Endpoints June 18 (Reuters) - AstraZeneca PLC AZN.L : ASTRAZENECA PLC - UPDATE ON CAPITELLO-290 PHASE III TRIAL ASTRAZENECA PLC - UPDATE ON CAPITELLO-290 PHASE III TRIAL ASTRAZENECA - SAFETY PROFILE OF TRUQAP IN COMBINATION WITH PACLITAXEL IN CAPITELLO-290 BRO
A

Ooh la la! London stocks snap at Paris' heels

LIVE MARKETS-Ooh la la! London stocks snap at Paris' heels STOXX 600 down 0.1% French politics weigh Sampo bids for Topdanmark Wall St futures steady Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com OOH LA LA! LONDON STOCKS SNAP AT PARIS' HEELS London is coming closer to knocking Paris off the top spot in terms of size of European stock markets, as the sell-off in French stocks ha
A
H
L
L
U
F
U
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.